Table 2: Profiles and clinical outcomes of patients who completed the regimen 

Clinical Background

 Immunological  Response

           Antitumor Response

Dose

Age

Gender

Origin

Status

HLA class I

   Tetramer
   increase

ELISPOT
increase

  RECIST

CEA

CA19-9

0.3 mg

63

Woman

Pancreas

Inoperable

+

   35

-17

  SD

Decreased

Decreased

0.3 mg

69

Woman

Pancreas

Inoperable

+

   5

-31

  SD

WNL

Increased

0.3 mg

53

Woman

Pancreas

Post-op

-

   7

6

  PD

Increased

Increased

0.3 mg

68

Man

Pancreas

Post-op

+

   +

17

  PD

Increased

Increased

0.3 mg

78

Man

Man

Post-op

+

   -4

2

  PD

Increased

Increased

1.0 mg

61

Man

Pancreas

Inoperable

+

   21

-1

  SD

Increased

Increased

1.0 mg

84

Woman

Colon

Post-op

+

   28

14

  SD

Increased

Increased

1.0 mg

69

Man

Stomach

Post-op

+

   7

26

  SD

Increased

Increased

1.0 mg

59

Man

Colon

Post-op

+

   29

16

  PD

Increased

Increased

1.0 mg

62

Man

Colon

Post-op

+

   15

2

  PD

Increased

WNL

3.0 mg

41

Woman

Pancreas

Post-op

+

   12

158

  SD

WNL

Stable

3.0 mg

66

Man

Pancreas

Inoperable

+

   12

19

  SD

Decreased

Increased

3.0 mg

64

Man

Pancreas

Post-op

+

    2

-16

  SD

WNL

Decreased

3.0 mg

50

Man

Pancreas

Post-op

+

   12

21

  PD

WNL

Increased

3.0 mg

64

Woman

Pancreas

Inoperable

+

   0

10

  PD

Increased

Increased



Post-op: Post-Operative, SD: Stable Disease, PD: Progressive Disease, WNL: Within the Normal Limit